Treating ectopic pregnancy with the combination of mifepristone and methotrexate: a phase II nonrandomized study.
OBJECTIVE
Our goal was to compare the use of a combination of methotrexate and mifepristone with methotrexate alone in the medical management of ectopic pregnancy.


METHODS
This was a preliminary nonrandomized phase II study. All patients with progressing ectopic pregnancy meeting criteria for medical management were included. Treatment consisted of 50 mg/m2 of methotrexate injected intramuscularly and 600 mg of mifepristone, administered orally, compared with a previous group who received only 50 mg/m2 of methotrexate injected intramuscularly.


RESULTS
Of the 30 patients treated with the combination, there was only 1 failure, whereas medical treatment had failed for 11 of 42 patients treated with methotrexate alone.


CONCLUSIONS
The combination of mifepristone and methotrexate decreased the risk of failure in medical treatment of ectopic pregnancy.
Department of Gynecology and Obstetrics, Poissy Hospital, University of Paris V, France.
M
M
Perdu
E
E
Camus
P
P
Rozenberg
F
F
Goffinet
C
C
Chastang
H J
HJ
Philippe
I
I
Nisand
D000021:Abortifacient Agents, Steroidal / Q000627:therapeutic use*; D000328:Adult; D006063:Chorionic Gonadotropin / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D015735:Mifepristone / Q000627:therapeutic use*; D011247:Pregnancy; D011271:Pregnancy, Ectopic / Q000097:blood / Q000188:drug therapy*; D012306:Risk; D017211:Treatment Failure
D000021:Abortifacient Agents, Steroidal; D006063:Chorionic Gonadotropin; D015735:Mifepristone; D008727:Methotrexate